For more than a year, U.S. authorities have been tightening a noose around Internet pharmacy company Canada Drugs, which reportedly was the source of counterfeit Avastin shipped last year to doctors.
Pfizer has run into the U.K. watchdog wall of resistance to targeted cancer drugs with its renal cancer treatment Inlyta.
Taiwan's TOT Biopharm has opened in mainland China the first phase of what it says is a $100 million plant for developing and manufacturing cancer drugs for the global market.
Cipla is roiling the waters in India again. Six months after slashing the prices on three cancer drugs--including a knockoff of Bayer's still-on-patent Nexavar--the company has issued another round of hefty price cuts.
Roche ($RHHBY) tried to sway the U.K.'s cost-effectiveness watchdogs toward its targeted melanoma drug Zelboraf. But it failed. The National Institute for Health and Clinical Excellence stuck to its rejection.
Canada's Sunshine BioPharma has tabbed CMO Beta Pharma to manufacture and help develop its developmental breast cancer treatment, Adva-27a.
Two words explain why Roche might well be the envy of Big Pharma: cancer drugs. The company posted sales growth, despite European pricing pressures, to $22.61 billion.
CMO Novasep is investing €3 million ($3.7 million) to expand its highly potent active pharmaceutical ingredient production, pouring the cash into its Le Mans, France, facility.
Some doctors and patients in Pakistan are now reportedly getting smuggled drugs in a special market set up in the famous Karkhano bazaar in Peshawar.
ScinoPharm is investing NT$1.1 billion ($37.6 million) in the construction of a plant in Tainan, Taiwan. The purpose of the plant: to produce injectable cancer drugs, according to the CMO.